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immunity, with both a universal vaccine and universal inﬂuenza
vaccination as the goals.
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The limitations of availabe antiviral agents, the M2 ion channel
nd neuraminidase inhibitors (NAIs), including resistance issues
ndicate the need for developing alternative agents.
Novel antivirals presently in clinical development include
ntravenous NAIs (oseltamivir, peramivir, zanamivir), long-acting
nhaled NAIs (laninamivir), attachment blockers (e.g., DAS181),
iral RNA polymerase inhibitors (e.g., ribavirin, favipiravir), passive
mmunotherapy (convalescent plasma, heterosubtypic neutral-
zing anti-HA stem monoclonals, anti-M2 monoclonals), and
nterferons.
Intravenous zanamivir and peramivir are undergoing active-
ontrolled study in patients hospitalized with serious inﬂuenza.
ne-time treatment with intravenous peramivir or inhaled lan-
namivir appears comparable to a standard 5-day regimen of
ral oseltamivir in uncomplicated inﬂuenza, and both agents are
pproved for use in Japan (peramivir also in South Korea). Of note,
anamivir and laninamivir are inhibitory for H275Y-containing N1
iruses. Orally inhalation of the HA receptor-destroying sialidase
AS 181 showed antiviral effects in uncomplicated inﬂuenza, and
he oral anti-parasitic agent nitazoxanide was recently reported to
ave beneﬁcial effects in a phase 2 study in ambulatory patients.
ther novel approaches include RNA interference, with one con-
truct targeting inﬂuenza M gene now in clinical study, and agents
hat inhibit host cell functions essential for inﬂuenza replication.
Combinations of inﬂuenza antivirals with differingmechanisms
f action can enhance antiviral activity and reduce resistance
mergence. One nonrandomized study of convalescent plasma for
andemic 2009 A(H1N1) patients reported signiﬁcantly reduced
ortality compared to NAI therapy alone, and an NIAID-sponsored
ontrolled study in hospitalized patients is in progress. One triple
egimen of oral amantadine, ribavirin, and oseltamivir (termed
CAD) shows greater antiviral activity than each dual combination,
nd a controlled study comparing TCAD to oseltamivir monother-
py is underway in at-risk ambulatory patients. One controlled
tudy in adults with uncomplicated inﬂuenza (primarily A/H3N2)
ound that oseltamivir alone was superior to a combination of
seltamivir and inhaled zanamivir. Combination studies involv-
ng antivirals and immunomodulatory interventions that might
ddress excessive or inadequate host responses are also needed.
Newer agentswill provide opportunities for studying drug com-
inations, coping with the problem of antiviral resistance, and
xpanding the therapeutic repertoire for inﬂuenza management,
specially in seriously ill patients and immunocompromised hosts.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.105nfectious Diseases 16S (2012) e2–e157
Type: Invited Presentation
Final Abstract Number: 24.004
Session: Update on Inﬂuenza
Date: Friday, June 15, 2012
Time: 15:45-17:45
Room: Ballroom B
Seasonal, pandemic, and inter-pandemic vaccines
L. Jennings
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Inﬂuenza vaccination is themost effectiveway to prevent infec-
tion and severe outcomes caused by inﬂuenza viruses. Recent avian
inﬂuenza and pandemic inﬂuenza events have highlighted major
gaps in our knowledgebase andability toproduce safe andeffective
vaccines timely,in response to these events. The seasonal inﬂuenza
vaccines currently in use are predominantly egg-derived inacti-
vated vaccines, which have consistently been shown to reduce the
risk of acquiring inﬂuenza and reduce the risk of hospitalisation and
of death. However their protection is antibody-mediated, strain-
speciﬁc and is dependent on the closeness of the match between
the vaccine strain and the circulating virus, so that developing vac-
cines with broader and longer lasting protection is a high priority.
Heightened concerns following the 2004 avian inﬂuenza epizootic
and the increased focus on pandemic preparedness planning have
led to the development of monovalent H5N1 vaccines, along with
an improvement in our knowledge surrounding pre-pandemic
vaccines; the need for cross-protection, the role of adjuvanted
vaccines and cell culture derived vaccines. Our response to the
H1N1pdm09 pandemic has highlighted novel vaccine develop-
ment, production and global supply issues. Increased capacity and
new technologies are needed to produce vaccines against a novel
inﬂuenza virus in sufﬁcient quantities to protect populations dur-
ing an emerging pandemic, not just the second wave. However,
in the inter-pandemic period we must address the lessons learnt
and remember that seasonal inﬂuenza provides an ongoing threat.
An understanding of a countries annual burden of disease from
inﬂuenza is the key driver for the establishment of inﬂuenza vac-
cination guidelines and vaccine uptake, while a clinician’s advice
is pivotal for an individual to receive inﬂuenza vaccine. A better
understanding of both B cell and T cell immunity will lead to vac-
cines with improved efﬁcacy and which provide heterosubtypic
